Previous 10 | Next 10 |
home / stock / crpof / crpof news
EDMONTON, Alberta, April 16, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO, OTCQX: CRPOF ) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and ...
EDMONTON, Alberta, April 15, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare...
EDMONTON, Alberta, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO; OTCQX: CRPOF ) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for health...
EDMONTON, Alberta, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare a...
– Ongoing clinical study evaluating the well-known health claims of beta glucan and its potentially beneficial approach for patients to lower plasma cholesterol – – Amendment to existing protocol approved to add subjects voluntarily limiting treatment to beta gluc...
EDMONTON, Alberta, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cos...
EDMONTON, Alberta, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industr...
EDMONTON, Alberta, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare an...
Ceapro ( OTC:CRPOF ): Q3 GAAP EPS of $0.00. More news on: Ceapro Inc., Earnings news and commentary, Consumer stocks news, , Read more ...
- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Maintained R&D focus on the development of delivery systems - - Third quarter 2019 sales and nine-month 2019 sales respectively increased 36.9% and 28.5% vs ...
News, Short Squeeze, Breakout and More Instantly...
TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, ...
– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,0...
Faraday Future Intelligent Electric Inc. (FFIE) is expected to report for Q1 2024 D-Market Electronic Services & Trading (HEPS) is expected to report for Q1 2024 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2024 Check-Cap Ltd. (CHEK) is expected to report $-0.17 for ...